NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
medline:
28
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
The clinical use of potent androgen receptor (AR) inhibitors has promoted the emergence of novel subtypes of metastatic castration-resistant prostate cancer (mCRPC), including neuroendocrine prostate cancer (CRPC-NE), which is highly aggressive and lethal
Identifiants
pubmed: 37502956
doi: 10.1101/2023.07.18.549585
pmc: PMC10370123
pii:
doi:
Types de publication
Preprint
Langues
eng